Singapore markets closed
Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,180.68 -1,144.15 (-1.84%) CMC Crypto 200
1,320.78 +20.68 (+1.59%)
Dynavax Technologies Corporation (DVAX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 11.76 |
| Open | 11.71 |
| Bid | 11.64 x 500 |
| Ask | 11.69 x 100 |
| Day's range | 11.64 - 11.85 |
| 52-week range | 10.67 - 15.15 |
| Volume | |
| Avg. volume | 1,998,659 |
| Market cap | 1.525B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.75 |
- GuruFocus.com
Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...
Explore the key financial outcomes and strategic insights from Dynavax Technologies Corp's first quarter of 2024, including significant revenue growth and enhanced gross margins.
ZacksDynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -40% and 2.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireDynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
© 2024 Yahoo. All rights reserved.